INHALED BECLOMETHASONE TO PREVENT CHRONIC LUNG DISEASE

这项研究旨在阐明新生儿 慢性肺部疾病的发生和吸入剂的容量和安全性的测试 糖皮质激素预防慢性肺病的进展及其临床意义 对生长发育的伴生影响。这将会实现的 通过一项随机、安慰剂对照的临床试验 皮质类固醇，二丙酸倍氯米松，用于小于1251克的婴儿 出生体重和妊娠33周以下的人，在3至14天内 年龄大了，继续需要机械通风。贝氯米松将会是 使用麻醉袋通过手动通风给药 带有间隔装置的计量吸入器，疗程28天。

This study has been designed to elucidate mechanisms by which neonatal chronic lung disease occurs and to test the capacity and safety of inhaled glucocorticoid to prevent the process of chronic lung disease and its accompanying effects on growth and developement. This will be accomplished through a randomized, placebo controlled clinical trial of inhaled corticosteroid, beclomethasone dipropionate, in infants less than 1251 gm birth weight and less than 33 weeks gestation who, at 3 to 14 days of age, continue to require mechanical ventilation. Beclomethasone will be administered via manual ventilation with an anesthesia bag using a metered dose inhaler with a spacer device for a 28-day treatment period.